WO2001072295A3 - Compositions and methods for the therapy and diagnosis of lung cancer - Google Patents

Compositions and methods for the therapy and diagnosis of lung cancer Download PDF

Info

Publication number
WO2001072295A3
WO2001072295A3 PCT/US2001/009991 US0109991W WO0172295A3 WO 2001072295 A3 WO2001072295 A3 WO 2001072295A3 US 0109991 W US0109991 W US 0109991W WO 0172295 A3 WO0172295 A3 WO 0172295A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
lung cancer
therapy
polypeptides
Prior art date
Application number
PCT/US2001/009991
Other languages
French (fr)
Other versions
WO2001072295A2 (en
Inventor
Steven G Reed
Michael J Lodes
Raodoh Mohamath
Heather Secrist
Darin R Benson
Carol Yoseph Indirias
Robert A Henderson
Steven P Fling
Paul A Algate
Mark Elliot
Jane Mannion
Michael D Kalos
Original Assignee
Corixa Corp
Steven G Reed
Michael J Lodes
Raodoh Mohamath
Heather Secrist
Darin R Benson
Carol Yoseph Indirias
Robert A Henderson
Steven P Fling
Paul A Algate
Mark Elliot
Jane Mannion
Michael D Kalos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/738,973 external-priority patent/US20020110563A1/en
Application filed by Corixa Corp, Steven G Reed, Michael J Lodes, Raodoh Mohamath, Heather Secrist, Darin R Benson, Carol Yoseph Indirias, Robert A Henderson, Steven P Fling, Paul A Algate, Mark Elliot, Jane Mannion, Michael D Kalos filed Critical Corixa Corp
Priority to CA002404233A priority Critical patent/CA2404233A1/en
Priority to HU0500345A priority patent/HUP0500345A2/en
Priority to AU2001261007A priority patent/AU2001261007A1/en
Priority to JP2001570256A priority patent/JP2004526401A/en
Priority to EP01934859A priority patent/EP1268797A2/en
Publication of WO2001072295A2 publication Critical patent/WO2001072295A2/en
Publication of WO2001072295A3 publication Critical patent/WO2001072295A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
PCT/US2001/009991 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer WO2001072295A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002404233A CA2404233A1 (en) 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer
HU0500345A HUP0500345A2 (en) 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer
AU2001261007A AU2001261007A1 (en) 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer
JP2001570256A JP2004526401A (en) 2000-03-29 2001-03-28 Compositions and methods for treatment and diagnosis of lung cancer
EP01934859A EP1268797A2 (en) 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US53803700A 2000-03-29 2000-03-29
US09/538,037 2000-03-29
US58893700A 2000-06-05 2000-06-05
US09/588,937 2000-06-05
US64087800A 2000-08-18 2000-08-18
US09/640,878 2000-08-18
US09/667,170 2000-09-20
US23451700P 2000-09-22 2000-09-22
US70451200A 2000-11-01 2000-11-01
US09/704,512 2000-11-01
US09/738,973 2000-12-14
US09/738,973 US20020110563A1 (en) 2000-11-01 2000-12-14 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (2)

Publication Number Publication Date
WO2001072295A2 WO2001072295A2 (en) 2001-10-04
WO2001072295A3 true WO2001072295A3 (en) 2002-08-22

Family

ID=27559252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009991 WO2001072295A2 (en) 2000-03-29 2001-03-28 Compositions and methods for the therapy and diagnosis of lung cancer

Country Status (7)

Country Link
JP (1) JP2004526401A (en)
AU (1) AU2001261007A1 (en)
CA (1) CA2404233A1 (en)
CZ (1) CZ20023567A3 (en)
HU (1) HUP0500345A2 (en)
PL (1) PL366626A1 (en)
WO (1) WO2001072295A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082212A1 (en) * 2000-07-20 2002-06-27 Millennium Pharmaceuticals, Inc. 7716, a novel human ATPase and uses therefor
WO2002092001A2 (en) * 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2003269557A1 (en) * 2002-10-18 2004-05-04 Lg Life Sciences Ltd. Gene families associated with cancers
DE10258051A1 (en) * 2002-12-11 2004-07-22 Metagen Pharmaceuticals Gmbh Use of substances that bind to HAT for the diagnosis and treatment of squamous cell carcinoma of the lungs
WO2004055183A2 (en) * 2002-12-17 2004-07-01 Fondazione Centro San Raffaele Del Monte Tabor Carcinoembryonic antigen-specific immunodominant epitope recognized by cd4+t cells and uses thereof
CN1761680A (en) 2002-12-26 2006-04-19 武田药品工业株式会社 Metastin derivative and use thereof
BRPI0512397A (en) 2004-06-25 2008-03-04 Takeda Pharmaceutical compound, pharmaceutical, methods for suppressing cancer metastasis or cancer growth, for preventing or treating a disease or condition, for controlling placental function, for improving gonadal function, for inducing or stimulating ovulation, for promoting secretion gonadotropic hormone or promote sex hormone secretion, to suppress gonadotropic hormone secretion or suppress sex hormone secretion, to regulate gonadrotopic hormone or sex hormone, and human ot7t175 protein, and to enhance blood stability, compound, and, an agent for suppressing gonadotropic hormone secretion or an agent for suppressing sex hormone secretion
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
TWI386417B (en) 2005-12-22 2013-02-21 Takeda Pharmaceutical Metastin derivatives and use thereof
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JP2007263896A (en) * 2006-03-29 2007-10-11 Univ Nagoya Biological marker for estimating post-operative prediction of lung cancer patient, and method therefor
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
JP5648261B2 (en) * 2006-12-20 2015-01-07 東レ株式会社 Cancer detection method
RU2519089C2 (en) * 2008-08-05 2014-06-10 Торэй Индастриз, Инк. Method for detection of malignant tumours
CA2733223C (en) 2008-08-05 2018-02-27 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
NZ592461A (en) 2008-10-22 2012-12-21 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
DK2532366T3 (en) 2010-02-04 2017-01-02 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
ES2543174T3 (en) 2010-02-04 2015-08-17 Toray Industries, Inc. Medicinal composition for the treatment and / or prevention of cancer
US8828398B2 (en) 2010-02-04 2014-09-09 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
HUE040012T2 (en) 2010-02-04 2019-02-28 Toray Industries Pharmaceutical agent for treatment and/or prevention of cancer
CN103717737B (en) 2011-08-04 2015-06-10 东丽株式会社 Cancer treatment and/or prevention drug composition
DK2740793T3 (en) 2011-08-04 2018-01-22 Toray Industries PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
KR102041832B1 (en) 2011-08-04 2019-11-08 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
US9273128B2 (en) 2011-08-04 2016-03-01 Toray Industries, Inc Pharmaceutical composition for treatment and/or prophylaxis of cancer
HUE039219T2 (en) 2011-08-04 2018-12-28 Toray Industries Pharmaceutical composition for treatment and/or prophylaxis of cancer
PL2741085T3 (en) 2011-08-04 2017-09-29 Toray Industries, Inc. Method for detecting pancreatic cancer
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2864864C (en) 2012-02-21 2020-05-12 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP6187257B2 (en) 2012-02-21 2017-08-30 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
JP6187258B2 (en) 2012-02-21 2017-08-30 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
JP6187256B2 (en) 2012-02-21 2017-08-30 東レ株式会社 Pharmaceutical composition for treatment and / or prevention of cancer
AU2013241043B2 (en) 2012-03-30 2017-11-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gall bladder cancer
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
US9772332B2 (en) 2012-07-19 2017-09-26 Toray Industries, Inc. Method for detecting CAPRIN-1 in a biological sample
HUE042081T2 (en) 2013-08-09 2019-06-28 Toray Industries Pharmaceutical composition for treatment and/or prevention of cancer

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2000060077A2 (en) * 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001079292A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
WO2001083553A2 (en) * 2000-05-03 2001-11-08 Pharmacia & Upjohn Company G protein-coupled receptors
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2000060077A2 (en) * 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001079292A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
WO2001083553A2 (en) * 2000-05-03 2001-11-08 Pharmacia & Upjohn Company G protein-coupled receptors
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751, XP002106655, ISSN: 0950-9232 *
DATABASE EMBL [online] 25 February 2000 (2000-02-25), HEILIG R ET AL.: "Sequencing of the human chromosome 14", XP002189438, Database accession no. AL15791 *
DATABASE EMBL [online] XP002200414, Database accession no. ABA09201 *
DATABASE EMBL/GENBANK [online] 18 February 1996 (1996-02-18), HILLIER L ET AL: "The WasU-Merck EST project", XP002189439, Database accession no. N54011 *
DATABASE SWISS PROT [online] 2 August 1999 (1999-08-02), SATO H ET AL.: "Homo sapiens mRNA for cystine/glutamate transporter, complete cds", XP002200340, Database accession no. AB026891 *
GÜRE A O ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041, XP002103188, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
PL366626A1 (en) 2005-02-07
JP2004526401A (en) 2004-09-02
AU2001261007A1 (en) 2001-10-08
HUP0500345A2 (en) 2005-07-28
WO2001072295A2 (en) 2001-10-04
CA2404233A1 (en) 2001-10-04
CZ20023567A3 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002074156A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002089747A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004052276A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002016413A8 (en) Cripto tumour polypeptide
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002014503A3 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
WO2002012328A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002039885A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002012280A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 570256

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2404233

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001934859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2002-3567

Country of ref document: CZ

ENP Entry into the national phase

Ref country code: RU

Ref document number: 2002 2002128922

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 018103588

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001934859

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3567

Country of ref document: CZ